Loading patent…
OwnerEdwin Oscar Schraa, Maria del Carmen Esandi +1inventors
InventorsEdwin Oscar Schraa, Maria del Carmen Esandi, Ronald Hendrik, P. Brus
Estimating the term…
The present invention provides methods for reducing the risks associated with administering adenoviral particles to subjects undergoing adenoviral gene therapy. In one aspect of the invention, at least one dose of adenovirus is administered to a subject to consequently allow the subject to mount an immune response against the adenovirus, the immune response allowing the subject to better tolerate gene therapy with a recombinant adenovirus containing a gene of interest. Preferably, the administered adenovirus is of the same serotype as the recombinant adenovirus to be used in gene therapy, or is of a serotype which is cross-reactive with the recombinant adenovirus serotype. In an alternate embodiment of the invention, a subject is provided with one or more doses of adenovirus-neutralizing antibodies administered prior to gene therapy with a recombinant adenovirus. In this aspect of the invention, parenteral administration of human antibodies or humanized antibodies is particularly preferred.
A kit of parts for gene delivery to a recipient cell in a host, using a gene delivery vehicle to which a humoral response can be raised, comprising a nucleic acid comprising a gene to be delivered to said recipient cell and further comprising a second composition of a second gene delivery vehicle essentially identical to said first gene delivery vehicle, but preferably lacking said gene to be delivered.
A method for delivering a gene of interest to a recipient cell in a host using a gene delivery vehicle comprising a nucleic acid comprising said gene of interest, said method comprising administering to a host a vaccine composition comprising a gene delivery vehicle lacking said gene to be delivered, allowing for a neutralising humoral response to be raised by said host to said gene delivery vehicle lacking said gene to be delivered and administering a composition for gene therapy comprising essentially the same gene delivery vehicle having a nucleic acid comprising said gene to be delivered in an amount greater than the amount which can be neutralised by said humoral response.
A method for avoiding or diminishing liver toxicity in a host of a gene delivery composition upon administration, comprising administering to a host a vaccine composition comprising a gene delivery vehicle, preferably lacking said gene to be delivered, allowing for a neutralising humoral response to be raised by said host to said gene delivery vehicle lacking preferably said gene to be delivered and administering a composition for gene therapy comprising essentially the same gene delivery vehicle having a nucleic acid comprising said gene to be delivered in an amount greater than the amount which can be neutralised by said humoral response.
Dependencies are inferred from the claim text.